Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | PHASE1 | COMPLETED | 25 | — | — | Feb 27, 2018 | Apr 27, 2022 | May 19, 2022 | 10 | United States |
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.
Maximum Tolerated or Administrated Dose of obrindatamab and retifanlimab
| Arm | Type | Description |
|---|---|---|
| obrindatamab + retifanlimab | EXPERIMENTAL | B7-H3 x CD3 DART protein + anti-PD-1 antibody |
| Name | Type | Description |
|---|---|---|
| obrindatamab | BIOLOGICAL | B7-H3 x CD3 DART protein |
| retifanlimab | BIOLOGICAL | anti-PD-1 antibody |
Inclusion Criteria: * Histologically-proven, unresectable locally advanced or metastatic solid tumors of any histology that test positive for B7-H3 expression on tumor cells or vasculature for whom no approved therapy with demonstrated clinical benefit is available. For all tumor types, the require...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |